THERAPY DOSSIER · th-c113c6a2d382

Nor-binaltorphimine (norBNI), a selective kappa-opioid receptor antagonist, given with morphine

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 4

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01913535 ↗PHASE2terminated

Proof-of-Concept Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

Treatment Resistant Depression

Enrolment: 8 · Results not recorded

NCT02218736 ↗PHASE2completed

Phase 2a Study of CERC-501 Engagement of Hedonic-Response Neural Circuitry in Mood and Anxiety Spectrum Disorders

Anxiety Disorders

Enrolment: 163 · Results not recorded

NCT01232439 ↗PHASE1completed

Brain Kappa Opioid Receptor Occupancy After Single Oral Doses of LY2456302 Measured by PET

Alcohol Dependence

Enrolment: 13 · Results not recorded

NCT01431586 ↗PHASE1terminated

Safety, Tolerability and Pharmacokinetics of Single Escalating Oral Doses of JDTic (kappa antagonist) in Healthy Male Subjects

Cocaine Dependence

Enrolment: 24 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27736318 ↗2016Mixed findings

Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury.

RatSpinal cord injuryContusionSprague-DawleyMalenorBNI 0, 0.02, 0.08 or 0.32 micromol, followed by morphine…24 hours after contusion, after baseline locomotor and nociceptive assessment

Model: Moderate spinal contusion at T12

The protective effect of norBNI was dose dependent. High doses blocked the adverse effect of morphine on locomotor recovery but markedly reduced analgesia, while low doses preserved analgesia but not recovery. An intermediate dose protected recovery while retaining analgesic efficacy, indicating th…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…